ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO763

Genome Engineering of Renal Epithelial Cells with Improved Function for an Implantable Artificial Kidney

Session Information

  • Bioengineering
    October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Bioengineering

  • 300 Bioengineering

Authors

  • Wilson, Matthew H., VA Medical Center, Nashville, Tennessee, United States
  • Luo, Wentian, Vanderbilt University Medical center, Nashville, Tennessee, United States
  • Veach, Ruth Ann, Vanderbilt University Medical center, Nashville, Tennessee, United States
  • Welch, Rick C., VUMC, Nashville, Tennessee, United States
  • Roy, Shuvo, UCSF, San Francisco, California, United States
  • Fissell, William Henry, Vanderbilt University Medical center, Nashville, Tennessee, United States
Background

Development of an implantable artificial kidney (IAK) will require renal epithelial cells capable of reabsorption of salt and water. We used genome engineering to bioengineer cells for improved Na+/H+ exchange and H20 reabsorption. The non-viral piggyBac transposon system enables genome engineering cells to stably overexpress one or more transgenes simultaneously. The CRISPR/Cas9 system (dCas9-VP64) enables selective endogenous gene upregulation in human cells.

Methods

We generated epitope tagged human sodium hydrogen exchanger 3 (NHE3) and aquaporin-1 (AQP1) cDNA expressing piggyBac transposon vectors. piggyBac transposase expression enabled stable transposon integration and overexpression of NHE3 or AQP1 in cultured renal epithelial cells. The transposon system was also used to integrate dCas9-VP64 into human kidney cells.

Results

As a proof-of-principle, we generated renal epithelial (MDCK) cells stably expressing a cumate inducible NHE3 and confirmed induced overexpression via Western blot and immunofluorescence analysis. We also generated MDCK cells stably overexpressing AQP1. Cell surface delivery of NHE3 and AQP1 was confirmed using cell surface biotinylation assays. Importantly, MDCK cells expressing AQP1 and cumate inducible NHE3 demonstrated increased cellular transport. We subsequently used a high-throughput flow cytometry analysis to generate a library of MDCK clones with varying expression of AQP1 and NHE3 to determine the best ratios for optimized transport function. We tested and validated various guide RNAs (gRNAs) for targeted upregulation of endogenous AQP1 and NHE3 in human kidney cells at both the mRNA and protein level.

Conclusion

Our results reveal that genome engineering can enable improved cellular transport via stable overexpression of AQP1 and NHE3 in polarized kidney epithelial cells. We are currently attempting to extend these studies to human renal proximal tubular epithelial (RPTEC) cells. Additionally, the dCas9-VP64 system enables upregulation of endogenous AQP1 and NHE3 in human kidney cells. These studies will allow us to determine the optimal genome engineering approach and renal epithelial cell type for maximal function in the IAK.

Funding

  • Other NIH Support